PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 PatientsSHIELD II Enrolled more than ...
Le Lézard2h
FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® ...
Hosted on MSN25m
Most New York voters would back banning workplace non-disclosure agreements: poll
A February poll indicated that most New York voters support banning companies from using NDAs to silence workers who report ...
Le Lézard15h
Spirit Airlines Proceeds With Standalone Recapitalization; Rejects Most Recent Proposal from Frontier
Spirit Airlines, Inc. ("Spirit" or the "Company") today provided an update on its restructuring process regarding a new proposal (the "New Proposal") for an alternative restructuring plan submitted by ...